Company intelligence / Profile preview
Shanghai Hepu Pharmaceutical
Shanghai, Shanghai Shi, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead clinical candidate, Hepalatide (a synthetic peptide targeting NTCP), is in phase II trials for chronic hepatitis B and D, with phase I safety completed; diabetes indication advancing towards IND submission in US.
- Therapeutic areas
- EndocrinologyInfectious DiseasesHematologyCardiovascularOncology
- Modalities
- Synthetic peptideSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Zhangjiang Biopharmaceutical Industry Venture Capital Co. Ltd.Shanghai Yuanxu Investment Management Co., Ltd.
Beyond the preview
Go deeper on Shanghai Hepu Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Hepu Pharmaceutical.